

November 25, 2009

NOSTRA-TRIAL - vasopharm is recruiting first patient in a phase IIa trial

Wuerzburg, Germany – November 25, 2009

vasopharm GmbH, a pharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases, today announced the recruitment of the first patient in its clinical phase IIa NOSTRA trial (NO-Synthase inhibition in TRAumatic brain injury).

The phase IIa is an explorative European multicentre placebo-controlled, randomized, double blind study examining safety and tolerability as well as pharmacodynamic and pharmacokinetic effects of the compound VAS203. VAS203 is novel type NO-synthase inhibitor competing with the co-factor tetrahydrobiopterin.

In total, 32 patients will be enrolled in five study centres. All study centres are routinely using the microdialysis technique which shall be instrumental to measure the NO- and energy metabolism as well as the presence of the compound in the brain tissue. The study is expected to run until the first quarter of 2011.

About vasopharm:

vasopharm is focused on the development of therapeutics which permits modulating the bioavailability of biological NO, by addressing the entire NO/cGMP signal cascade and its functional counterpart NOX. vasopharm's drug candidate VAS203 represents a completely new class of NOS modulators targeting cerebral vessels and cerebral tissue, thus preventing life threatening rises in intracranial pressure.

May 04, 2009

vasopharm closes € 4.5 million Series D Investment

Wuerzburg, Germany – May 04, 2009

vasopharm GmbH today announced the successful completion of its Series D financing round amounting to € 4.5 million (~ \$ 6 million). The investment was led by EMBL Ventures, Heidelberg, Germany. Additional investors participating in this round were Entrepreneurs Fund, London, UK, HeidelbergCapital Private Equity, Heidelberg, Germany as well as KfW, Frankfurt am Main, Germany.

The Series D financing round is primarily dedicated to an explorative European multicenter clinical phase IIa study exploring vasopharm's compound VAS 203. All participating centers use routinely the technique of microdialysis in order to investigate acute pharmacodynamic effects of the compound during a three days lasting infusion. Intracranial pressure of the patients will also be monitored during this time.

VAS203 is an allosteric nitric oxide synthase inhibitor for the treatment of traumatic brain injury. It has demonstrated safety and tolerability in two clinical phase I studies with single and repetitive dosing schedules.
